# Phase 2 thrombocytopenia trials recruiting: 21 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials in phase 2 for thrombocytopenia that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 thrombocytopenia trials: 21 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/thrombocytopenia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 21
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2026 | NCT07936201 | Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and Thrombocytopenia | Case Comprehensive Cancer Center | Phase 2 | Not yet recruiting | Myelofibrosis | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936201) |
| November 12, 2026 | NCT07933146 | Sequential Hetrombopag and Recombinant Human Thrombopoietin for Cancer Therapy-Induced Thrombocytopenia | The First Affiliated Hospital of Zhengzhou University | Phase 2 | Not yet recruiting | Thrombocytopenia | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933146) |
| October 26, 2026 | NCT07895017 | Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias | University of Virginia | Phase 2 | Not yet recruiting | Thrombocytopenia | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895017) |
| September 21, 2026 | NCT07829952 | Efficacy and Safety of Romiplostim N01 for Injection in Promoting Platelet Reconstitution After Allogeneic Hematopoietic Stem Cell... | The First Affiliated Hospital of Henan University of Science and Technology | Phase 2 | Not yet recruiting | Thrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829952) |
| June 15, 2026 | NCT07647029 | A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae | Fudan University | Phase 2 | Recruiting | Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT) | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07647029) |
| May 14, 2026 | NCT07586826 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or... | Peking University People's Hospital | Phase 2 | Recruiting | Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers... | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07586826) |
| May 14, 2026 | NCT07586813 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid... | Peking University People's Hospital | Phase 2 | Recruiting | Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gastrointestinal... | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07586813) |
| March 4, 2026 | NCT07447817 | Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias | Sponsor not shown (see the record) | Phase 2 | Recruiting | Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07447817) |
| March 2, 2026 | NCT07441720 | Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) | Zhejiang Cancer Hospital | Phase 2 | Recruiting | Thrombocytopenia, Cancer Treatment-induced Thrombocytopenia | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441720) |
| December 12, 2025 | NCT07278661 | Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. | Nantes University Hospital | Phase 2 | Recruiting | Chirurgical Intervention, Thrombocytopaenia | 142 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07278661) |
| December 9, 2025 | NCT07273721 | Efficacy and Safety of BT200 (Rondaptivon Pegol) in Patients With Type 2B Von Willebrand Disease | Medical University of Vienna | Phase 2 | Recruiting | Von Willebrand Disease (VWD), Type 2 | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07273721) |
| December 2, 2025 | NCT07257809 | Herombopag Treated T-DM1 Induced Platelet Reduction | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Recruiting | Thrombocytopenia | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07257809) |
| January 23, 2025 | NCT06788691 | Luspatercept for Clonal Cytopenias of Uncertain Significance | Weill Medical College of Cornell University | Phase 2 | Recruiting | CCUS Clonal Cytopenia of Undetermined Significance, Anemia, Leukopenia, Thrombocytopenia, Neutropenia | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06788691) |
| December 20, 2024 | NCT06745219 | Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer | Peking University Cancer Hospital & Institute | Phase 2 | Not yet recruiting | Thrombopenia, Cervical Cancer, Radiotherapy Side Effect, Chemotherapeutic Toxicity | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06745219) |
| November 5, 2024 | NCT06673498 | Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease... | Anhui Provincial Hospital | Phase 2 | Recruiting | Thrombocytopenia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06673498) |
| September 19, 2024 | NCT06599762 | Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia | University of Manitoba | Phase 2 | Recruiting | Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic/Myeloproliferative Neoplasm | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06599762) |
| August 21, 2023 | NCT05998759 | Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia | Beijing Hospital | Phase 2 | Recruiting | Connective Tissue Diseases, Thrombocytopenia | 296 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05998759) |
| August 8, 2023 | NCT05980806 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | Karyopharm Therapeutics Inc | Phase 2 | Recruiting | Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05980806) |
| January 20, 2022 | NCT05199909 | Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Antiphospholipid Syndrome, Thrombocytopenia, Treatment | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05199909) |
| September 8, 2021 | NCT05037760 | A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis | Takeda | Phase 2 | Recruiting | Myelofibrosis | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05037760) |
| March 11, 2020 | NCT04304820 | Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | Recruiting | Severe Aplastic Anemia | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04304820) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Peking University People's Hospital | 2 |
| The First Affiliated Hospital of Zhengzhou University | 1 |
| Weill Medical College of Cornell University | 1 |
| Fudan University | 1 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 1 |
| Medical University of Vienna | 1 |
| The First Affiliated Hospital of Henan University of Science and Technology | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| Zhejiang Cancer Hospital | 1 |
| University of Virginia | 1 |
| University of Manitoba | 1 |
| Anhui Provincial Hospital | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| [Karyopharm Therapeutics Inc](https://specstream.ai/data/clinical-trials/company/karyopharm-therapeutics-inc) | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Beijing Hospital | 1 |
| Case Comprehensive Cancer Center | 1 |
| Nantes University Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 10 |
| United States | 6 |
| France | 3 |
| Italy | 2 |
| South Korea | 2 |
| Spain | 2 |
| United Kingdom | 2 |
| Canada | 2 |
| Australia | 1 |
| Brazil | 1 |
| Austria | 1 |
| Belgium | 1 |
| Bulgaria | 1 |
| Czechia | 1 |
| Denmark | 1 |
| Germany | 1 |
| Greece | 1 |
| Hungary | 1 |
| Israel | 1 |
| Netherlands | 1 |
| Poland | 1 |
| Romania | 1 |
| Taiwan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Insurance agencies in the United States](https://specstream.ai/data/businesses/insurance-agencies/united-states)
- [Fire and water damage restoration companies in the United States](https://specstream.ai/data/businesses/fire-and-water-damage-restoration-companies/united-states)
- [Court reporters in the United States](https://specstream.ai/data/businesses/court-reporters/united-states)
- [Beauty product suppliers in the United States](https://specstream.ai/data/businesses/beauty-product-suppliers/united-states)
- [3D printing companies in the United States](https://specstream.ai/data/businesses/3d-printing-companies/united-states)
- [Suppliers and distributors in the United States](https://specstream.ai/data/businesses/suppliers-and-distributors/united-states)
